Toll Free: 1-888-928-9744

NanoViricides, Inc. - Product Pipeline Review - 2015

Published: Oct, 2015 | Pages: 40 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

NanoViricides, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'NanoViricides, Inc. - Product Pipeline Review - 2015', provides an overview of the NanoViricides, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of NanoViricides, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of NanoViricides, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of NanoViricides, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the NanoViricides, Inc.'s pipeline products

Reasons to Buy

- Evaluate NanoViricides, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of NanoViricides, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the NanoViricides, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of NanoViricides, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of NanoViricides, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of NanoViricides, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents
2 List of Tables 4 List of Figures 4 NanoViricides, Inc. Snapshot 5 NanoViricides, Inc. Overview 5 Key Information 5 Key Facts 5 NanoViricides, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 NanoViricides, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 NanoViricides, Inc. - Pipeline Products Glance 11 NanoViricides, Inc. - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Discovery Products/Combination Treatment Modalities 12 NanoViricides, Inc. - Drug Profiles 13 DengueCide 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 EKCCide-I 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Herpecide 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 HIVCide-I 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 NVINF-1 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 NVINF-2 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 RabiCide-I 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Small molecule for Ebola and Marburg Infections 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ADIFBase-I 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 HIVCide-II 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Small Molecule for Middle East Respiratory Syndrome Human Coronavirus Infection 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 NanoViricides, Inc. - Pipeline Analysis 26 NanoViricides, Inc. - Pipeline Products by Target 26 NanoViricides, Inc. - Pipeline Products by Route of Administration 27 NanoViricides, Inc. - Pipeline Products by Molecule Type 28 NanoViricides, Inc. - Pipeline Products by Mechanism of Action 29 NanoViricides, Inc. - Recent Pipeline Updates 30 NanoViricides, Inc. - Dormant Projects 36 NanoViricides, Inc. - Discontinued Pipeline Products 37 Discontinued Pipeline Product Profiles 37 AviFluCide-I 37 FluCideHP-I 37 NanoViricides, Inc. - Locations And Subsidiaries 38 Head Office 38 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 39 Disclaimer 40
List of Tables
NanoViricides, Inc., Key Information 5 NanoViricides, Inc., Key Facts 5 NanoViricides, Inc. - Pipeline by Indication, 2015 7 NanoViricides, Inc. - Pipeline by Stage of Development, 2015 9 NanoViricides, Inc. - Monotherapy Products in Pipeline, 2015 10 NanoViricides, Inc. - Preclinical, 2015 11 NanoViricides, Inc. - Discovery, 2015 12 NanoViricides, Inc. - Pipeline by Target, 2015 26 NanoViricides, Inc. - Pipeline by Route of Administration, 2015 27 NanoViricides, Inc. - Pipeline by Molecule Type, 2015 28 NanoViricides, Inc. - Pipeline Products by Mechanism of Action, 2015 29 NanoViricides, Inc. - Recent Pipeline Updates, 2015 30 NanoViricides, Inc. - Dormant Developmental Projects,2015 36 NanoViricides, Inc. - Discontinued Pipeline Products, 2015 37



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify